Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Children & TeensPractice MgmtNeuropathyIssue 664

Routine Screening for DPN in Children Needs to be Mandatory

Study calls for clinical guidelines for detecting DPN (diabetic peripheral neuropathy) in young patients….

Advertisement

The researchers reported that 26% of 151 children with Type 1 diabetes, aged 8 to 21 years, had a positive screening test for DPN.

This included six (75%) of eight patients at high-risk for DPN -- defined as age 13 years or older, diabetes duration of at least 5 years, and a HbA1c level of 10% or higher on two of the previous four measurements.

But 33 (23%) of the 143 patients who did not meet these risk criteria also had a positive screening test for DPN, which included a modified version of the Michigan Neuropathy Screening Inventory, a foot inspection, ankle reflex testing, monofilament (10 g) examination, and tuning fork testing. Follow-up with a pediatric neurologist confirmed DPN in five (62.5%) of the high-risk and 11 (46.0%) of the low-risk patients.

The average age of patients with confirmed DPN was 16.2 years. Although the average HbA1c was 8.7%, seven patients had a level equal to or below 8%. Average duration of diabetes in the DPN group was 6.4 years, but two patients had been diagnosed with diabetes within the past year.

Indeed, there was no significant correlation between diagnosis of DPN and patient age, duration of diabetes, HbA1c or cholesterol level, or height at puberty, although the researchers say this may be due to sample size or the cross-sectional study design.

This study highlights that DPN can occur in youth at any age and at any time from the onset of diagnosis.

Researchers added that, "These data raise our awareness of DPN in youth and challenge us to incorporate routine screening in practice as supported by research done outside of the US."

Diabetes Research and Clinical Practice, Feb 2013

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 15 February, 2013 and appeared in  Children & TeensPractice MgmtNeuropathyIssue 664

Past five issues: Issue 766 | Diabetes Clinical Mastery Series Issue 225 | Issue 765 | Diabetes Clinical Mastery Series Issue 224 | Issue 764 |

2015 Most Popular Articles:

Significant Weight Loss and Drop in A1c with New Combo of Lorcaserin and Phentermine
Posted January 16, 2015
ADA Issues New Standards of Medical Care for Diabetes
Posted January 02, 2015
New Guideline Released on Pharmacological Management of Obesity
Posted January 23, 2015
For Your Patients: Practical Advice to Rev Up Your Workouts and Lower Fatigue
Posted January 09, 2015
Dr. Timothy Garvey on Qsymia and Other New Therapies for Weight Loss
Posted January 12, 2015
Phentermine and Topirimate ER (Qsymia) Studied for Type 2 Diabetes Patients
Posted January 15, 2015
Handbook of Diabetes, 4th Ed., Excerpt #25: Specific Circumstances that Affect Diabetes Control
Posted January 04, 2015
New Insulin Glargine 300 Effective in Type 1 Diabetes
Posted January 16, 2015
FDA Approves Maestro Electronic Weight Loss Device
Posted January 23, 2015
New Guidelines Recommend Off-Loading to Increase Likelihood of Diabetic Foot Ulcer Healing
Posted December 26, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Will you prescribe inhaled insulin (Afrezza) when it becomes available this year?
CME/CE of the Week
William Tamborlane, MD, FAAP, FACE

Category: General Diabetes
Credits:
 .75
Search Articles On Diabetes In Control